DK0475352T3 - 3-(1H-Indazol-3-yl)-4-pyridinaminer, fremgangsmåde og mellemprodukter til deres fremstilling og deres anvendelse som lægemidler - Google Patents

3-(1H-Indazol-3-yl)-4-pyridinaminer, fremgangsmåde og mellemprodukter til deres fremstilling og deres anvendelse som lægemidler

Info

Publication number
DK0475352T3
DK0475352T3 DK91115280.9T DK91115280T DK0475352T3 DK 0475352 T3 DK0475352 T3 DK 0475352T3 DK 91115280 T DK91115280 T DK 91115280T DK 0475352 T3 DK0475352 T3 DK 0475352T3
Authority
DK
Denmark
Prior art keywords
hydrogen
loweralkyl
pyridinamines
indazol
intermediates
Prior art date
Application number
DK91115280.9T
Other languages
Danish (da)
English (en)
Inventor
Richard Charles Effland
Joseph Thomas Klein
Original Assignee
Hoechst Roussel Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Roussel Pharma filed Critical Hoechst Roussel Pharma
Application granted granted Critical
Publication of DK0475352T3 publication Critical patent/DK0475352T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK91115280.9T 1990-09-10 1991-09-10 3-(1H-Indazol-3-yl)-4-pyridinaminer, fremgangsmåde og mellemprodukter til deres fremstilling og deres anvendelse som lægemidler DK0475352T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/579,751 US5051430A (en) 1990-09-10 1990-09-10 3-(1H-indazol-3-yl)-4-pyridinamines

Publications (1)

Publication Number Publication Date
DK0475352T3 true DK0475352T3 (da) 1995-10-16

Family

ID=24318208

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91115280.9T DK0475352T3 (da) 1990-09-10 1991-09-10 3-(1H-Indazol-3-yl)-4-pyridinaminer, fremgangsmåde og mellemprodukter til deres fremstilling og deres anvendelse som lægemidler

Country Status (20)

Country Link
US (1) US5051430A (no)
EP (1) EP0475352B1 (no)
JP (1) JP3042915B2 (no)
KR (1) KR100203236B1 (no)
AT (1) ATE123493T1 (no)
AU (1) AU640590B2 (no)
CA (1) CA2050875C (no)
CZ (1) CZ280883B6 (no)
DE (1) DE69110219T2 (no)
DK (1) DK0475352T3 (no)
ES (1) ES2074618T3 (no)
FI (1) FI914219A (no)
HU (1) HUT59126A (no)
IE (1) IE67442B1 (no)
IL (1) IL99434A (no)
NO (1) NO913543L (no)
NZ (1) NZ239692A (no)
PL (1) PL295728A1 (no)
PT (1) PT98911B (no)
ZA (1) ZA917141B (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT56347A (en) * 1989-12-27 1991-08-28 Hoechst Roussel Pharma Process for producing aminopyridinylmethanol and aminomethyl pyridineamine derivatives and pharmaceutical compositions comprising such compounds
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US7211594B2 (en) 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
WO2002083648A1 (en) * 2001-04-16 2002-10-24 Eisai Co., Ltd. Novel 1h-indazole compound
EP1720855A4 (en) * 2004-03-02 2008-12-17 Smithkline Beecham Corp HEMMER OF ACT ACTIVITY
CN101213191B (zh) * 2005-03-30 2011-08-24 （株）大熊制药 抗真菌三唑衍生物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU198036B (en) * 1983-08-22 1989-07-28 Hoechst Roussel Pharma Process for production of derivatives of 3-piperidil-/1h/-indasole and medical preparatives containing them

Also Published As

Publication number Publication date
DE69110219D1 (de) 1995-07-13
IL99434A (en) 1995-08-31
IE67442B1 (en) 1996-04-03
JPH04247079A (ja) 1992-09-03
NZ239692A (en) 1994-01-26
IE913157A1 (en) 1992-03-11
ZA917141B (en) 1992-04-29
FI914219A (fi) 1992-03-11
CA2050875C (en) 2002-07-16
KR920006346A (ko) 1992-04-27
NO913543L (no) 1992-03-11
ATE123493T1 (de) 1995-06-15
ES2074618T3 (es) 1995-09-16
PT98911A (pt) 1992-07-31
PL295728A1 (en) 1993-05-04
KR100203236B1 (ko) 1999-06-15
DE69110219T2 (de) 1995-11-09
EP0475352B1 (en) 1995-06-07
AU640590B2 (en) 1993-08-26
CA2050875A1 (en) 1992-03-11
IL99434A0 (en) 1992-08-18
AU8371691A (en) 1992-03-12
PT98911B (pt) 1999-02-26
CS277691A3 (en) 1992-04-15
HUT59126A (en) 1992-04-28
HU912901D0 (en) 1992-01-28
NO913543D0 (no) 1991-09-09
JP3042915B2 (ja) 2000-05-22
CZ280883B6 (cs) 1996-04-17
US5051430A (en) 1991-09-24
EP0475352A1 (en) 1992-03-18
FI914219A0 (fi) 1991-09-06

Similar Documents

Publication Publication Date Title
NO903851L (no) Fremgangsmaate for fremstilling av n-substituerte-4-pyrimidinaminer og -pyrimidindiaminer, og deres anvendelse som medikamenter.
DK0637586T3 (da) 2-(Piperidin-4-yl, pyridin-4-yl og tetrahydropyridin-4-yl)-benzofuran-7-carbamatderivater, deres fremstilling og anvendelse
DK0402752T3 (da) N-Heteroaryl-purin-6-aminer, fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler
DK0498331T3 (da) N-(Aryloxyalkyl)-heteroaryl-8-azabicyclo(3.2.1)octaner, mellemprodukter og en fremgangsmåde til fremstilling deraf samt deres anvendelse som lægemidler
DK0475352T3 (da) 3-(1H-Indazol-3-yl)-4-pyridinaminer, fremgangsmåde og mellemprodukter til deres fremstilling og deres anvendelse som lægemidler
DK0413191T3 (da) 1-(Pyridinylamino)-2-pyrrolidinoner, fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler
DK0471297T3 (da) 3-(1,2-Benzisoxazol-3-yl)-4-pyridinaminer og derivater
DK1049672T3 (da) Azetidincarboxamid-derivater til behandling af CNS-lidelser
DK0545425T3 (da) 2-(3-Phenylpropyl)hydraziner, fremgangsmåde til deres fremstilling, mellemprodukter dertil og deres anvendelse som lægemidler